PHASQ Stock Plummets 99% on Pink Sheets Exchange May 6

PHASQ stock has collapsed to near-zero levels, trading at just $0.000001 USD on the pink sheets exchange (PNK) as of May 6, 2026. The 99% decline reflects PhaseBio Pharmaceuticals’ ongoing bankruptcy restructuring following its October 2022 Chapter 11 filing. This clinical-stage biopharmaceutical company, once focused on cardiovascular treatments, now trades with minimal liquidity and volume. The stock’s catastrophic fall underscores the risks inherent in early-stage biotech investments, particularly when clinical trials face setbacks or funding challenges. Investors holding PHASQ stock face severe losses with limited recovery prospects.

PHASQ Stock Price Collapse and Trading Activity

PHASQ stock has reached penny stock status with virtually no trading value. The stock trades at $0.000001 per share, down from a previous close of $0.0001. This represents a staggering 99% single-day loss. Trading volume sits at just 2,500 shares, compared to an average daily volume of 22,310 shares. The year-to-date performance shows consistent deterioration, with the stock down 99.99% over the past year. The 52-week range spans from $0.000001 to $0.0399, illustrating the dramatic devaluation. Market capitalization has effectively zeroed out, making PHASQ one of the market’s most distressed securities.

PhaseBio Pharmaceuticals’ Bankruptcy and Pipeline Status

PhaseBio Pharmaceuticals filed for Chapter 11 bankruptcy protection in October 2022, fundamentally altering the company’s trajectory. The Malvern, Pennsylvania-based firm was developing three main drug candidates targeting cardiovascular diseases. Its lead asset, bentracimab (PB2452), was a reversal agent for ticagrelor in Phase III trials. The company also pursued PB1046 for pulmonary arterial hypertension and PB6440 for resistant hypertension. Despite these promising programs, funding constraints and clinical challenges forced the bankruptcy filing. The company maintains approximately 60 full-time employees and continues limited operations. Track PHASQ on Meyka for real-time updates on restructuring developments.

Financial Metrics and Fundamental Deterioration

PHASQ’s financial metrics reveal severe operational distress across all key indicators. The company reports negative earnings per share of -$2.14, with a price-to-earnings ratio that’s essentially meaningless at these valuations. Operating cash flow remains deeply negative at -$1.08 per share, while free cash flow stands at -$1.14 per share. The current ratio of 1.75 suggests some short-term liquidity, but this masks broader insolvency concerns. Book value per share is -$2.12, indicating negative shareholder equity. Research and development spending consumes 942% of revenue, reflecting the pre-commercial nature of the biotech pipeline. These metrics underscore why PHASQ stock has become essentially worthless.

Market Sentiment and Liquidation Outlook

Market sentiment around PHASQ remains deeply negative with minimal institutional interest. Trading activity has dried up significantly, with relative volume at just 11.2% of average. The stock’s presence on the pink sheets (PNK) rather than major exchanges limits accessibility and transparency. Analyst coverage has disappeared entirely, leaving retail investors without professional guidance. The bankruptcy process will likely determine final shareholder recovery, which appears minimal given the company’s liabilities. Meyka AI rates PHASQ with a grade of B based on fundamental analysis, though this reflects pre-bankruptcy metrics. Recovery scenarios remain highly speculative, and most investors should consider PHASQ stock a total loss for tax purposes.

Final Thoughts

PHASQ stock represents a cautionary tale in biotech investing, having collapsed from promising cardiovascular drug development to near-total worthlessness. The 99% crash to $0.000001 reflects the brutal reality of clinical-stage pharmaceutical companies facing funding shortfalls and bankruptcy. PhaseBio Pharmaceuticals’ Chapter 11 restructuring offers minimal hope for equity holders, as creditors typically receive priority in reorganization proceedings. The company’s pipeline—including bentracimab, PB1046, and PB6440—may have value to acquirers, but shareholders will likely receive nothing. This case demonstrates why diversification and risk management are essential in biotech portfol…

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.